- Home
- KURA vs DSGN Comparison
KURA vs DSGN Comparison
Compare KURA & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | DSGN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 853.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KURA | DSGN |
|---|---|---|
| Price | $10.91 | $12.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $25.56 | $15.25 |
| AVG Volume (30 Days) | ★ 1.8M | 669.5K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $106.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $7.36 | $5.28 |
| 52 Week High | $13.90 | $17.25 |
Technical Indicators
Market Signals| Indicator | KURA | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 36.97 |
| Support Level | $8.45 | $11.82 |
| Resistance Level | $11.40 | $13.54 |
| Average True Range (ATR) | 0.48 | 0.75 |
| MACD | -0.18 | -0.26 |
| Stochastic Oscillator | 6.75 | 7.12 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.